{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-096243","form_type":"8-K","ticker":"TARA","cik":"0001359931","company_name":"Protara Therapeutics, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.252782+00:00","generated_at":"2026-05-30T01:40:12.417674+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Protara Therapeutics reports Q3 2024 net loss of $11.2M; cash $81.5M; pipeline on track","bullets":["Net loss $11.2M ($0.50 per share) vs $9.9M ($0.87) in Q3 2023; no revenue.","Cash, equivalents, and investments $81.5M as of Sept 30; sufficient to fund operations into 2026.","R&D expenses $8.1M; G&A $4.3M; stock-based comp $0.9M.","On track to report interim 6-month data from TARA-002 in NMIBC ADVANCED-2 trial in 4Q 2024.","FDA Fast Track granted for IV Choline Chloride; THRIVE-3 first patient dosing expected in 1Q 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-096243","json":"https://secwatch.observer/filing/0001213900-24-096243.json","markdown":"https://secwatch.observer/filing/0001213900-24-096243.md","text":"https://secwatch.observer/filing/0001213900-24-096243.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1359931/000121390024096243/0001213900-24-096243-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1359931/000121390024096243/ea0219258-8k_protara.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:40:12.417674+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}